Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O00337

UPID:
S28A1_HUMAN

ALTERNATIVE NAMES:
Concentrative nucleoside transporter 1; Na(+)/nucleoside cotransporter 1; Sodium-coupled nucleoside transporter 1; Solute carrier family 28 member 1

ALTERNATIVE UPACC:
O00337; A0AV42; A8K7I2; O00335; O00336; Q5U5S6; Q5U648; Q9UEZ9

BACKGROUND:
The Sodium-coupled nucleoside transporter 1, identified as Solute carrier family 28 member 1, is integral to the cellular uptake of pyrimidine nucleosides and adenosine. This transporter's operation is essential for maintaining nucleoside pools within cells, critical for DNA and RNA synthesis. Its unique transport characteristics classify it within the N2/cit nucleoside transport system, highlighting its specificity and functional importance in cellular physiology.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Sodium-coupled nucleoside transporter 1 could open doors to potential therapeutic strategies. Its involvement in Uridine-cytidineuria suggests that modulating its activity might offer new avenues for correcting metabolic anomalies associated with nucleoside transport dysfunctions, thereby contributing to the development of targeted treatments for related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.